Stass, Sanford

Open Protocols

Protocol Name Investigatory Role Biomarkers Data Collections
Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer - Supplemental Pre-Validation Protocol Involved 0 0
Indeterminate pulmonary nodule biomarker clinical utility trial Involved 0 0
Molecular Basis of Barrett's -Associated Carcinogenesis Leading 0 0
Non-coding RNAs as Biomarkers for Early Detection of Lung Cancer in Sputum Coordinating 34 0
Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2) Involved 15 1

Closed Protocols

Protocol Name Investigatory Role Biomarkers Data Collections
Detection of Bladder CA by Microsatellite Analysis (MSA) Involved 16 0
Validation of Biomarkers for the Early Detection of Colorectal Adenocarcinoma (GLNE 010) Involved 4 0

Publications

Publication NamePubMed IDJournal
A panel of sputum-based genomic marker for early detection of lung cancer. 20864512 Cancer Prev Res (Phila)
A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. 28376184 J Natl Cancer Inst
A Prediction Model Based on Biomarkers and Clinical Characteristics for Detection of Lung Cancer in Pulmonary Nodules. 27889655 Transl Oncol
Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. 20142235 Cancer Epidemiol Biomarkers Prev
Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. 19276181 Mol Cancer Res
ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. 20010854 Lab Invest
Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. 19446359 Lung Cancer
Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas. 23330000 Int J Clin Exp Pathol
An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. 14996713 Cancer Res
Analysis of Lung Flute-collected Sputum for Lung Cancer Diagnosis. 26309391 Biomark Insights
Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. 24305007 J Thorac Oncol
Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis. 26246471 Oncotarget
C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology. 18784824 Int J Clin Exp Pathol
Characterization of microRNA transcriptome in lung cancer by next-generation deep sequencing. 24785186 Mol Oncol
Combined genetic analysis of sputum and computed tomography for noninvasive diagnosis of non-small-cell lung cancer. 19181417 Lung Cancer
Detecting genomic aberrations by fluorescence in situ hybridization with quantum dots-labeled probes. 18283800 J Nanosci Nanotechnol
Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer. 26146958 Lab Invest
Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. 23474761 Oncogene
Evaluation of lung flute in sputum samples for molecular analysis of lung cancer. 24053570 Clin Transl Med
Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. 17255269 Clin Cancer Res
Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing. 25159866 Int J Cancer
Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. 16369491 Oncogene
Magnetic enrichment of bronchial epithelial cells from sputum for lung cancer diagnosis. 18484646 Cancer
MicroRNAs as potential biomarkers in human solid tumors. 23196059 Cancer Lett
Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. 19223503 Clin Cancer Res
Prediction of survival in patients with esophageal carcinoma using artificial neural networks. 15751017 Cancer
Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. 20572039 Cancer
Sputum long non-coding RNA biomarkers for diagnosis of lung cancer. 31450489 Cancer Biomark
Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. 25593345 Clin Cancer Res
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. 19072545 J Proteome Res
Summarizing performance for genome scale measurement of miRNA: reference samples and metrics. 29510677 BMC Genomics
Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. 18345035 Oncogene
Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. 17699796 Cancer Res

Interests

cancer biomarkers development and validation
The development and validation of cancer biomarkers is an area of interest, experience and expertise of Dr. Stass. He has been involved in the the development and validation of multiple cancer biomarkers. After a cancer biomarker has been developed the validation needs to be performed in a CLIA certified laboratory environment using standard operating procedures. Dr. Stass directs and has extensive experience in overseeing cancer biomarker validation in a CLIA laboratory environment.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Photograph of Stass, Sanford
Site
University of Maryland School of Medicine
Degree(s)
M.D.
Email
sstass@som.umaryland.edu
Fax
410-328-1813
Person ID
1821
Note
To update contact information, please visit the Data Management and Coordinating Center .